Month: November 2017

I first got to work with V.A.C. VERAFLO™ Therapy in 2015. I had a complex patient who had a very large wound from a surgical wound dehiscence after a lymphedema thigh lobule excision. She was growing a variety of bacteria, and the surgical team managed her wound with Acetic Acid packings BID. After a week and a half of no clinical improvement, heavy nursing time, and use of IV narcotics, they called the wound care team for management. I applied V.A.C. VERAFLO™ Therapy with 100mL of 0.25% acetic acid to her wound and was able to transfer her to a lower level of care within one week … read more

Patients often sue for reasons that have nothing to do with the quality of the medical care rendered, but rather for the human care that is perceived as lacking.

The last few weeks were very difficult for my family and friends in the medical sense. I had one family member in an intensive care unit on the West Coast, one friend’s father in a rehab facility on the East Coast, and one friend’s son having problems in the outpatient setting in the Midwest. These patients are male and female, young and old, and have very different medical histories, but they all have one thing in common. They all want to sue about their medical care or lack thereof. These cases illustrate three common reasons you might get sued …. read more

Off-label drug use and questionable documentation are just two wound care bad habits that can get clinicians into trouble. Don’t just accept it because “We’ve Always Done It This Way” .

As clinicians, we use our knowledge, training and experience to find solutions and take care of patients in the best way possible. We learn about standards of care, scope of practice, and facility policies and procedures to guide our actions and care-giving …

read more

Are your wound cleansing practices up-to-date? Find out with these top tips for cleaning wounds properly and choosing the right cleansers.

When you get clinicians together to talk about wounds, dressing choices are usually a popular topic. Wound cleansing? Not so much.

The first patient has been dosed in a Phase III trial assessing ViroMed’s VM202, the first pivotal study of a gene therapy indicated for patients with nonhealing diabetic foot ulcers (NHU) and concomitant peripheral artery disease (PAD).

The Phase III trial (NCT02563522) is a double-blind, placebo-controlled, multicenter study designed to evaluate VM202 for safety and efficacy in 300 adults with a diabetic foot ulcer and concomitant PAD. Two hundred patients will be randomized to VM202 and the other 100 to placebo, ViroMed’s U.S. division VM BioPharma said yesterday. … read more